Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403

Abstract Over-expression of BCL-2 defines follicular lymphoma (FL). Venetoclax (VEN), a selective BCL-2 inhibitor, has previously been evaluated with bendamustine-based chemoimmunotherapy. VEN was given continuously, resulting in promising efficacy but unacceptable toxicity. The Phase II PrE0403 stu...

Full description

Saved in:
Bibliographic Details
Main Authors: Craig A. Portell, Opeyemi A. Jegede, Nina Wagner-Johnston, Grzegorz S. Nowakowski, Christopher Fletcher, Jonathon B. Cohen, Andrew M. Evens, Lori J. Rosenstein, Jeffrey W. Craig, Nishitha Reddy, Brad S. Kahl
Format: Article
Language:English
Published: Nature Publishing Group 2025-05-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-025-01300-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41408-025-01300-1

Similar Items